

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): August 30, 2024**

---

**FIBROGEN, INC.**

(Exact name of Registrant as Specified in Its Charter)

---

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-36740**  
(Commission File Number)

**77-0357827**  
(IRS Employer  
Identification No.)

**409 Illinois Street**  
**San Francisco, California**  
(Address of Principal Executive Offices)

**94158**  
(Zip Code)

**Registrant's Telephone Number, Including Area Code: 415 978-1200**

(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.01 par value	FGEN	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

As part of the continuing efforts of FibroGen, Inc. (the “Company”) to implement a significant cost reduction plan in the U.S., which was initiated on August 2, 2024, the Company provided notice of termination to two executive officers on August 30, 2024, each of whom will remain with the Company through a transition period: Juan Graham, Chief Financial Officer and Deyaa Adib, M.D., Chief Medical Officer. Mr. Graham’s planned departure date is December 15, 2024 and Dr. Adib’s planned departure date is November 1, 2024. The Company would like to thank Mr. Graham and Dr. Adib for their service and for the many contributions they made as Chief Financial Officer and Chief Medical Officer, respectively, and as members of the executive team. The employment decisions for Mr. Graham and Dr. Adib are not the result of any disagreement with the Company.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

FIBROGEN, INC.

Date: September 6, 2024

By: /s/ Michael Lowenstein

Michael Lowenstein  
Chief Legal Officer

---

